CRL vs HSIC

CRL presents a contradictory profile characterized by a very weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. While the company maintains a strong track record of beating earnings estimates and carries an attractive Forward P/E of 13.76, negative profit margins and declining YoY revenue and EPS growth are concerning. The valuation appears discounted (PEG 0.13), but the bearish technical trend and poor health score offset the bullish analyst consensus. Overall, the stock is a value play contingent on a fundamental turnaround that is not yet evident in the data.

HSIC exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the current price of $75.34 is well above the defensive Graham Number ($45.41), it trades at a discount to its growth-based intrinsic value of $89.60 and the analyst target of $89.23. The company shows positive YoY revenue and earnings growth, though thin profit margins and bearish insider sentiment provide a cautionary counterweight. Overall, the valuation appears attractive on a forward P/E basis (12.82) relative to its historical stability.